Wall Street closed in the red on Thursday as escalating geopolitical tensions surrounding U.S.-Iran relations and a disappointing earnings miss from Chinese e-commerce giant Alibaba overshadowed a string of positive corporate results. Investors remain on edge as Congress debates war funding and the Fed’s leadership comes under renewed scrutiny.
Market Performance: A Sea of Red
All three major indices retreated in Thursday’s session, with the Dow Jones Industrial Average (DIA) leading losses at -0.42%, closing at $461.06. The S&P 500 (SPY) edged down 0.25% to settle at $659.80, while the tech-heavy NASDAQ (QQQ) slipped 0.32% to $593.02.
The modest pullback reflects a market caught between solid domestic earnings and a rapidly evolving international crisis. Trading volumes remained elevated as institutional investors repositioned portfolios amid heightened uncertainty.
Geopolitical Storm: Iran Dominates Headlines
The specter of military conflict loomed large over trading floors Thursday. A massive Trump administration funding request for potential Iran military operations faces fierce opposition on Capitol Hill, with lawmakers from both parties expressing reservations about the scope and scale of the proposed engagement.
Adding fuel to the fire, a Reuters/Ipsos poll revealed that a majority of Americans believe the administration will deploy ground troops to Iran—and they strongly oppose such action. President Trump drew a controversial parallel between Pearl Harbor and recent U.S. strikes on Iran during a meeting with Japan’s Prime Minister, raising eyebrows among diplomatic observers.
Meanwhile, Israeli Prime Minister Netanyahu’s comments about routing oil and gas through Israel post-conflict suggest regional allies are already positioning for a dramatically reshaped Middle East energy landscape. Trump reportedly urged Israel to refrain from repeating strikes on Iranian energy infrastructure as the crisis continues to deepen.
Fed Drama Continues
In Washington, President Trump signaled that the Department of Justice should continue its investigation into Federal Reserve Chair Jerome Powell, a development that could complicate the anticipated nomination of Kevin Warsh as Powell’s successor. The ongoing pressure on Fed independence rattled some investors, though bond markets showed relatively muted reactions.
Earnings Spotlight: FedEx Delivers, Alibaba Stumbles
Thursday’s earnings calendar was packed with reports across multiple sectors, delivering a mixed but generally constructive picture of corporate America.
Winners:
- FedEx (FDX) stole the show with an impressive beat, posting EPS of $5.25 versus estimates of $4.16. The logistics giant’s results suggest resilient consumer spending and healthy e-commerce activity despite economic headwinds.
- Signet Jewelers (SIG) sparkled with EPS of $6.25, narrowly topping the $6.17 consensus, signaling continued strength in discretionary spending.
- Fly Leasing (FLY) reported a loss of $0.38 per share, but handily beat the expected loss of $0.48, suggesting improving conditions in the aircraft leasing market.
- Movado Group (MOV) delivered EPS of $0.57 against estimates of $0.54, demonstrating resilience in the luxury watch segment.
- Snail Inc. (SNAL) and Prothena (PTHS) also topped expectations, with losses narrower than analysts had projected.
Disappointments:
- Alibaba (BABA) was the day’s biggest letdown, posting EPS of $6.96 against lofty expectations of $11.88—a substantial miss that sent shares lower in after-hours trading. The results highlight ongoing challenges in China’s consumer economy and increased regulatory pressures.
- Canadian Solar (CSIQ) reported a loss of $1.66 per share, far worse than the expected $0.62 loss, as the solar sector continues to grapple with margin compression and oversupply.
- Arcos Dorados (ARCO), the McDonald’s Latin America franchise operator, missed estimates with a $0.04 loss versus expected profits of $0.20.
Healthcare Watch: Wegovy Gets a Boost
In pharmaceutical news, the FDA approved a higher-dose version of Novo Nordisk’s blockbuster weight loss drug Wegovy, as the Danish drugmaker fights to reclaim market share in the increasingly competitive obesity treatment space. The approval could help Novo Nordisk fend off challenges from Eli Lilly’s Zepbound.
Looking Ahead
As we head into Friday’s session, investors will continue monitoring developments in the Middle East, where any escalation could trigger significant volatility across energy markets and risk assets. The Fed leadership saga adds another layer of uncertainty to an already complex macro environment.
With earnings season winding down, attention will shift back to economic data releases and forward guidance from corporate executives. For now, caution appears to be the watchword on Wall Street.
Stay tuned for tomorrow’s market briefing as this dynamic situation continues to unfold.
Leave a Reply